Molecular biology of 5,10-methylenetetrahydrofolate reductase

Journal of Nephrology

Volumn 13, Issue 1, 2000, Pages 20-33

  Födinger, Manuela ^a   Hörl, Walter H ^b   Sunder Plassmann, Gere ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biochemistry; Disease causing mutations; Folate; Genetics; Homocysteine; Methylenetetrahydrofolate reductase; Polymorphisms

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; HOMOCYSTEINE; METHIONINE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE;

ALLELE; AMINO ACID METABOLISM; CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LONGEVITY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEURAL TUBE DEFECT; PREECLAMPSIA; PREGNANCY; PROTEIN VARIANT; REVIEW; VEIN THROMBOSIS;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; FEMALE; FOLIC ACID; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; NEOPLASMS; NEURAL TUBE DEFECTS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; VENOUS THROMBOSIS;

EID: 1642586763     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Kutzbach C, Stokstad EL. Mammalian methylenetetrahydrofolate reductase. Partial purification, properties, and inhibition by S-adenosylmethionine. Biochim Biophys Acta 1971; 250: 459-77.
2. Goyette P, Sumner J, Milos R, Duncan A, Rosenblatt D, Matthews R, Rozen R. Isolation of a cDNA for human methylenetetrahydrofolate reductase (MTHFR) and identification of mutations in MTHFR-deficient patients. Am J Hum Genet 1993; 53: A153 (abstract).
3. Daubner SC, Matthews RG. Purification and properties of methylenetetrahydrofolate reductase from pig liver. J Biol Chem 1982; 257: 140-5.
4. Hillman RS. Hematopoietic agents: growth factors, minerals, and vitamins. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics. Goodman and Gilman's. New York; Pergamon Press 1990; 1277-310.
5. Leclerc D, Wilson A, Dumas R, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95: 3059-64.
6. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7: 195-200.
7. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-3.
8. Goyette P, Pai A, Milos R, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mammalian Genome 1998; 9: 652-6.
9. Chen GH, Zhang CH, Zhang XY, et al. Cloning and expression of 5,10 methylenetetrahydrofolate reductase (MTHFR) gene. Science China Series C Life Science 1998; 41: 636-43 .
10. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998; 95: 13217-20.
11. Molloy AM, Daly S, Mills JL, et al. Thermolabile variant of 5,10 methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349: 1591-3.
12. van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube defects? Am J Hum Genet 1998; 62: 1044-51.
13. Molloy AM, Mills JL, Kirke PN, Whitehead AS, Weir DG, Scott JM. Whole blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and micriobiological assays. Clin Chem 1998; 44: 186-8.
14. Viel A, Dall'Agnese L, Simone F, et al. Loss of heterozygosity at the 5,10 methylenetetrahydrofolate reductase locus in human ovarian carcinomas. Br J Cancer 1997; 75: 1105-10.
15. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-72.
16. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 1258-60.
17. McAndrew PE, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylenetetrahydrofolate reductase in African Americans. Thromb Res 1996; 83: 195-8.
18. Hegele RA, Wolever TM, Hanley AJ, Harris SB, Zinman B. Methylenetetrahydrofolate reductase gene, dietary folate, NIDDM, and atherosclerosis in Canadian Oji-Cree. Diabetes Care 1998; 21: 322-3.
19. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-21.
20. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-54.
21. Blom HJ. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr 1998; 157 (suppl 2): S131-4.
22. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
23. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4.
24. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation laeds to hyperhomocysteinemia but not to vascular disease. The results of a meta-analysis. Circulation 1998; 98: 2520-6.
25. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary artery disease incidence in relation to fasting homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
26. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 1998: 9: 533-9.
27. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049-57.
28. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
29. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28: 1739-13.
30. Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylenetetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol 1999; 20: 357-61.
31. Harmon DL, Doyle RM, Meleady R, et al. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999; 19: 208-11.
32. Soriente L, Coppola A, Madonna P, et al. Homozygous C677T. mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke 1998; 29: 869-71. (letter)
33. Monta H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998; 18: 1465-9.
34. Lalouschek W, Aull S, Series W, et al. C677T MTHFR mutation and factor V Leiden mutation in patients wth TIA / minor stroke: a case-control study. Thromb Res 1999; 93: 61-9.
35. Demuth K, Moatti N, Hanon O, Benoit MO, Safar M, Girerd X. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler Thromb Vasc Biol 1998; 18: 1838-43.
36. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
37. Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-5.
38. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: Possible mechanism for pathological consequences of elevated homocysteine levels.J Biol Chem 1997; 272: 1935-42.
39. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
40. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
41. Boers GH. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520-2.
42. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-6.
43. Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 907-11.
44. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arteriosler Thromb Vasc Biol 1999; 19: 511-8.
45. Salden A, Keeney S, Hay CR, Cumming AM. The C677T MTHFR variant and the risk of venous thrombosis. Br J Haematol 1997; 99: 472 (letter).
46. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylenetetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997; 97: 804-6.
47. Cattaneo M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V: Q506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
48. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-8.
49. Kluijtmans LA, Boers GH, Verbruggen B, Trijbles FJ, Novakova IR, Blom HJ. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 1998; 91: 2015-8.
50. Legnani C, Palareti G, Grauso F, et al. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol 1997; 17: 2924-9.
51. Alhenc-Gelas M, Arnaud E, Nicaud V, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.
52. Gemmati D, Previati M, Serino ML, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocysteinemia in normal and thromboembolic subjects. Arterioscl Thromb Vasc Biol 1999; 19: 1761-7.
53. Rees DC, Liu YT, Cox MJ, Elliott P, Wainscoat JS. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age. Thromb Haemost 1997; 78: 1357-9.
54. Galinsky D, Tysoe C, Brayne CE, et al. Analysis of the apo E / apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Atherosclerosis 1997; 129: 177-83.
55. Harmon DL, McMaster D, Shields DC, Whitehead AS, Rea IM. MTHFR thermolabile genotype frequencies and longevity in Northern Ireland. Atheroslerosis 1997; 131: 137-8 (letter).
56. Brattstrom L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 1998; 141: 315-9.
57. Matsushita S, Muramatsu T, Arai H, Matsui T, Higuchi S. The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population. Am J Hum Genet 1997; 61: 1459-60.
58. Heijmans BT, Gussekloo J, Kluft C, et al. Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet 1999; 7: 197-204.
59. Faure-Delanef L, Quéré I, Chassé JF, et al. Methylenetetrahydrofolate reductase thermolabile variant and human longevity. Am J Hum Genet 1997; 60: 999-1001.
60. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1.
61. Posey DL, Khoury MJ, Mulinare J, Adams MJ jr, Ou CY. Is mutated MTHFR a risk factor for neural tube defects? Lancet 1996; 347: 686-7.
62. Stevenson RE, Schwartz CE, Du YZ, Adams MJ. Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 1997; 60: 229-30 (letter).
63. van der Put NM, Eskes TK, Blom HJ. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997; 90: 111-5.
64. Ou CY, Stevenson RE, Brown VK, et al. 5,10 methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996; 63: 6104.
65. Wilcken DE. MTHFR 677C→T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease. Lancet 1997; 350: 603 (commentary).
66. Molloy AM, Mills JL, Kirke PN, et al. Low blood folates in NTD pregnancies are only partly explained by thermolabile 5,10-methylenetetrahydrofolate reductase: low folate status alone may be the critical factor. Am J Med Genet 1998; 78: 155-9.
67. Christensen B, Arbour L, Tran B, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999; 84: 151-7.
68. Rajkovic A, Catalano PM, Malinow MR. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 1997; 90: 168-71.
69. Powers RW, Minich LA, Lykins DL, Ness EB, Cromble-holme WR, Roberts JM. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest 1999; 6: 74-9.
70. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997; 34: 525-6.
71. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052-1.
72. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9.
73. Nelen WL, Steegers EA, Eskes TK, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997; 350: 861 (letter).
74. Grandone E, Margaglione M, Colaizzo D, et al. Methylene tetrahydrofolate reductase (MTHFK) 677 mutation and unexplained early pregnancy loss. Thromb Haemostas 1998; 79: 1056-7.
75. Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ. Infant C677T mutation in MTHFR, maternal periconceptional vitamin use, and cleft lip. Am J Med Genet 1998; 80: 196-8.
76. Grandone E, Margaglione M, Colaizzo D, et al. Prothrombotic genetic risk factors and the occurence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81: 349-52.
77. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutrition 1998; 128: 1336-41.
78. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998; 352: 454 (letter).
79. Arai K, Yamasaki Y, Kajimoto Y, et al. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 1997; 46: 2102-4.
80. Smyth JS, Savage DA, Maxwell AP. MTHFR gene polymorphism and diabetic nephropathy in type 1 diabetes. Lancet 1999; 353: 1156-7.
81. Bluthner M, Bruntgens A, Schmidt S, Strojek K, Grzeszczak W, Ritz E. Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes? Nephrol Dial Transplant 1999; 14: 56-7.
82. Odawara M, Yamashita K. A common mutation of the methylenetetrahydrofolate reductase gene as a risk factor for diabetic nephropathy (submitted).
83. Vychytil A, Fodinger M, Wolfl G, et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 1998; 53: 1775-82.
84. Födinger M, Mannhalter C, Wolfl G, et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997: 52: 517-23.
85. Brulhart MC, Dussoix P, Ruiz J, Passa P, Froguel PH, James RW. The (Ala Val) Mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients Am J Hum Genet 1997; 60: 228-9.
86. Kamiya H, Kawakami K, Miyanaga T, et al. A methylenetetrahydrofolate reductase polymorphism is associated with expression of p 16 in human lung cancer. Oncol Rep 1998; 5: 911-4.
87. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-102.
88. Pereira P, Stanton V, Jothy S, Tomlinson IP, Foulkes WD, Rozen R. Loss of heterozygosity of methylenetetrahydrofolate reductase in colon cancer. Oncol Rep 1999: 6: 597-9.
89. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997; 18: 2307-11.
90. Mudd SH, Freeman JM. N-5,10-methylenetetrahydrofolate reductase deficiency and schizophrenia: a working hypothesis. J Psychiatr Res 1974; 11: 259-62.
91. Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to a deficient 5,10 methylenetetrahydrofolate reductase activity. N Engl J Med 1975; 292: 491-6.
92. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet 1997; 74: 526-8.
93. Regland B, Germgard T, Gottfries CG, Grenfeldt B, Koch-Schmidt AC. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Transm 1997; 104: 931-41.
94. Kunugi H, Fukuda R, Hattori M, et al. C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatr 1998; 3: 435-7.
95. Wei J, Hammings GP. Allelic association of the MTHFR gene with schizophrenia. Mol Psychiatr 1999; 4: 115-6.
96. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 74.
97. Fodinger M, Wolfl G, Fischer G, et al. Effect of MTHFR 677G→T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999; 1072-80.
98. Liangos O, Kreutz R, Beige J, Offermann G, Distler A, Sharma AM. Methylenetetrahydrofolate-reductase gene variant C677T and kidney transplant survival. Nephrol Dial Transplant 1998; 13: 2351-4.
99. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998; 141: 161-6.
100. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-62.
101. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-54.
102. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Velle D, eds. The metabolic basis of inherited disease. New York: McGraw-Hill 1989; 2049-64.
103. Shih VE, Salam MZ, Mudd SH, Uhlendorf BW, Adams RD. A new form of homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. Pediatr Res 1972; 6: 135 (abstract).
104. Kanwar YS, Manaligod JR, Wong PW. Morphologic studies in a patient with homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Pediatr Res 1976; 10: 598-609.
105. de Baulny HO, Gerard M, Saudubray JM, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr 1998; 157 (suppl 2): S77-83.
106. Rosenblatt DS, Erbe RW. Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency. Pediatr Res 1977; 11: 1141-3.
107. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-9.
108. Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutations in eis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am J Hum Genet 1996; 59: 1268-75.
109. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19: 589-94.
110. Kluijtmans LA, Wendel U, Stevens EM, van den Heuvel LP, Trijbels F, Blom HJ. Identification of four novel mutations in severe methylenetetrahydrofolate reductase deficiency. Eur J Hum Genet 1998; 6: 257-65.
111. Sunder-Plassmann G, Födinger M. Pathophysiology and clinical importance of hyperhomocysteinemia: Clinical intervention studies. Mineral Elect Metab, (in press).